Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma

Next Previous
X
Search
Trial Profile

Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzastaurin (Primary) ; Lomustine
  • Indications Glioblastoma; Gliosarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms STEERING
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 11 Jan 2022 This trial has been completed in Germany (End Date: 23 May 2014), according to European Clinical Trials Database record.
    • 22 Mar 2012 Planned end date changed from 1 Apr 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned end date changed from Apr 2010 to Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top